10-K: Iovance Biotherapeutics 2025 Annual Report Highlights Amtagvi Growth

Iovance Biotherapeutics reports increased Amtagvi revenue and ongoing clinical trials, alongside a net loss of $391.0 million for fiscal year 2025.

Summary

• Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for solid tumor cancers.
• Amtagvi (lifileucel) is the first one-time, individualized T cell therapy approved for adult patients with previously treated advanced, or unresectable or metastatic melanoma, launched in the U.S. and Canada.
• Amtagvi has the potential to address more than 30,000 previously treated advanced melanoma patients annually.
• Clinical data from the C-144-01 trial showed Amtagvi achieved a 31.4% objective response rate (ORR), median duration of response (mDOR) of 36.5 months, and five-year overall survival (OS) of 19.7%.
• Real-world data for Amtagvi demonstrated a physician-assessed ORR of 44% and a disease control rate of 73% among 41 evaluable patients.
• Proleukin (aldesleukin), an interleukin-2 product, is also sold and used in the Amtagvi treatment regimen and other oncology applications.
• The Iovance Cell Therapy Center (iCTC) in Philadelphia is the first FDA-approved facility for commercial TIL cell therapy manufacturing, with a potential capacity to supply therapies for over 5,000 cancer patients annually.
• All Amtagvi and lifileucel manufacturing activities are transitioning to the iCTC, with the contract manufacturer concluding production in the first quarter of 2026.
• The development pipeline includes ongoing registrational trials: TILVANCE-301 for frontline advanced melanoma (in combination with pembrolizumab) and IOV-LUN-202 for previously treated advanced non-small cell lung cancer (NSCLC).
• Updated preliminary data for IOV-LUN-202 (39 evaluable patients) showed an ORR of 25.6%, a disease control rate of 71.8%, and mDOR not reached after a median follow-up of 25.4 months.
• A registrational trial for previously treated advanced undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS) is planned to commence in the second quarter of 2026.
• Next-generation clinical programs include IOV-3001 (second-generation IL-2 analog, Phase 1/2 dose escalation), IOV-4001 (PD-1 inactivated TIL, Phase 2 efficacy extension), and IOV-5001 (IL-12 expression, IND submission planned in H1 2026).
• The company reported a net loss of $391.0 million for the year ended December 31, 2025, an increase from $372.2 million in 2024.
• Total product revenue increased by 61% to $263.5 million in 2025, up from $164.1 million in 2024.
• Amtagvi revenue was $220.0 million in 2025, a 112% increase from $103.6 million in 2024.
• Proleukin sales decreased to $43.5 million in 2025 from $60.5 million in 2024.
• Cash, cash equivalents, short-term investments, and restricted cash totaled $303.0 million as of December 31, 2025.
• A strategic restructuring plan in August 2025, including a 19% workforce reduction, resulted in $5.1 million in restructuring charges.
• The accumulated deficit reached $2.8 billion as of December 31, 2025.
• An Amended and Restated Open Market Sale Agreement with Jefferies was entered into in August 2025, allowing for the sale of up to $350.0 million of common stock, with $306.3 million in net proceeds received in 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral-to-slightly-negative report. While Amtagvi revenue growth and pipeline progress are positive, the increasing net loss, significant cash burn, and regulatory delays in the EU and a past clinical hold indicate ongoing challenges and financial pressures.

Positives

• Amtagvi product revenue significantly increased to $220.0 million in 2025, up 112% from $103.6 million in 2024, demonstrating strong commercial launch traction.
• Overall product revenue grew by 61% to $263.5 million in 2025, driven by Amtagvi's commercialization.
• Amtagvi's clinical data from the C-144-01 trial showed unprecedented durability with a 31.4% ORR, 36.5 months mDOR, and 19.7% five-year OS in previously treated advanced melanoma patients.
• Positive real-world data for Amtagvi reinforced clinical efficacy, showing a 44% ORR and 73% disease control rate.
• The Iovance Cell Therapy Center (iCTC) is FDA-approved for commercial TIL manufacturing and has the potential capacity to supply therapies for over 5,000 cancer patients annually, enhancing scalability and control.
• The company is advancing a robust pipeline with two ongoing registrational trials (TILVANCE-301 for frontline advanced melanoma and IOV-LUN-202 for previously treated advanced NSCLC).
• A new registrational trial for previously treated advanced undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS) is planned for Q2 2026, with engagement with the FDA for expedited approval.
• Progress in next-generation TIL therapies (IOV-3001, IOV-4001, IOV-5001) indicates continued innovation and potential for future growth.
• A leading intellectual property portfolio includes over 330 granted or allowed U.S. and international patents, providing Amtagvi with exclusivity into 2042.
• A favorable OIG advisory opinion was received in 2024 regarding patient travel and lodging support, mitigating fraud and abuse risks for a key patient support program.

Negatives

• The company incurred a net loss of $391.0 million in 2025, an increase from $372.2 million in 2024, indicating continued significant cash burn.
• An accumulated deficit of $2.8 billion as of December 31, 2025, highlights the long-term unprofitability.
• Proleukin sales decreased by 28% to $43.5 million in 2025, partially offsetting Amtagvi's revenue growth.
• Cost of sales increased by 86% to $173.2 million in 2025, driven by Amtagvi manufacturing costs, a $9.5 million increase in excess and obsolescence reserve for Proleukin, and $18.1 million in period costs related to patient drop-off and manufacturing failures.
• Restructuring charges of $5.1 million were incurred in 2025 due to a 19% workforce reduction.
• Interest and other income, net, decreased by 49% to $10.3 million in 2025, primarily due to a non-recurring gain in 2024 and lower average investment balances and interest rates.
• The initial Marketing Authorization Application (MAA) for Amtagvi in the European Union was withdrawn in July 2025, requiring resubmission in 2026, delaying market entry.
• A partial clinical hold was placed on the IOV-LUN-202 trial from Q4 2023 into Q1 2024 due to a reported Grade 5 (fatal) serious adverse event, pausing patient enrollment.
• The company faces significant competition from other biotechnology and pharmaceutical companies with greater resources and established products.
• Ongoing legal proceedings, including derivative lawsuits and intellectual property disputes, pose financial and reputational risks.

Risks

• The company has a history of operating losses and expects to continue incurring losses, with no guarantee of future profitability.
• Additional financing will be required to fund operations, complete product development, and commercialization, potentially leading to stockholder dilution or restrictive covenants.
• Manufacturing of complex cell-based therapies is susceptible to difficulties in production, quality control, and scaling-up, which could delay supply or increase costs.
• Reliance on limited or sole source vendors for critical biological raw materials, chemicals, reagents, and specialized equipment could impair manufacturing and supply.
• Uncertainties exist regarding market acceptance, third-party reimbursement coverage, and the commercial potential of novel product candidates.
• There is no assurance that the Gen 2 manufacturing process will be FDA-compliant, more efficient, or lower the cost to manufacture TIL products.
• Significant competition from other biotechnology and pharmaceutical companies, as well as non-profit institutions, could limit market share and pricing power.
• Projections regarding market opportunities for products and product candidates may be inaccurate, leading to smaller actual markets.
• Limited commercial experience may hinder the establishment of effective marketing and sales capabilities, limiting revenue generation.
• Post-marketing requirements and studies, including confirmatory trials like TILVANCE-301, may be imposed as a condition of approval, requiring substantial investment.
• Difficulties in managing organizational growth, including recruiting and retaining qualified personnel, could impact business operations.
• Reliance on third parties for essential services (distribution, price reporting, customer service, adverse event reporting) exposes the company to performance and compliance risks.
• Inability to successfully or sufficiently expand manufacturing capacity could prevent meeting demand for products.
• Product candidates may fail to successfully complete development, receive regulatory approval, or be successfully commercialized.
• Development of product candidates for use in combination with already approved products may present additional challenges and complexities.
• Expedited regulatory designations (Fast Track, Breakthrough Therapy, RMAT) do not guarantee faster development, review, or ultimate marketing approval.
• Orphan Drug Designation may not be maintained or provide the anticipated benefits, including market exclusivity.
• Substantial delays in clinical trials, or requirements for additional or modified trials based on regulatory feedback, could impact timelines and costs.
• Clinical trials may fail to adequately demonstrate the safety and efficacy of product candidates, preventing or delaying regulatory approval.
• Substantial royalties and lump sum benchmark payments are required under existing license and acquisition agreements (NIH, Novartis, Clinigen, Cellectis).
• Reliance on governmental, academic, and corporate partners for research and development carries risks of incorrect or unreliable results due to lack of control over manufacturing methods.
• Global operations expose the company to risks such as changes in medical reimbursement policies, trade protection measures, foreign exchange fluctuations, and diminished intellectual property protection.
• Economic uncertainty, geopolitical instability, ongoing military conflicts, and inflation could materially adversely affect business, financial condition, and results of operations.
• Internal computer systems, or those of third-party contractors, may fail or suffer security breaches, potentially leading to data loss, liability, or delays.
• The adoption and use of artificial intelligence (AI) technology may expose the company to risks from defects, security breaches, loss of data, and an evolving regulatory framework.
• Health epidemics and pandemics could adversely affect business operations, clinical trial sites, third-party manufacturers, and supply chains.
• Failure to comply with international data protection laws and regulations (e.g., GDPR) could lead to government enforcement actions and significant penalties.
• Future acquisitions or strategic partnerships may increase capital requirements, dilute stockholders, incur debt, or assume contingent liabilities.
• Increased sensitivity to environmental, social, and governance (ESG) concerns may lead to new requirements and increased costs.
• Extensive and costly regulation by the FDA and foreign authorities can lead to unanticipated delays in obtaining and maintaining approvals.
• Political uncertainty and potential legal, regulatory, and policy changes by government administrations (e.g., tariffs, drug pricing policies) may adversely impact operating performance.
• Employees, independent contractors, consultants, commercial partners, and vendors may engage in misconduct or improper activities, leading to noncompliance with regulatory standards.
• Involvement in lawsuits to protect or enforce patents, or accusations of patent infringement, could be expensive, time-consuming, and unsuccessful.
• Changes in U.S. patent law could diminish the value of patents, impairing the ability to protect products.
• Limited foreign intellectual property rights may hinder protection of inventions globally.
• Claims that employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties could lead to litigation.

Future Outlook

The company expects to continue incurring significant operating losses as it invests in clinical and internal research and development programs and executes the Amtagvi launch. Plans include launching Amtagvi into additional markets like the UK and Australia in the first half of 2026, and Switzerland in 2027, along with resubmitting the MAA in the EU in 2026. A new registrational trial for previously treated advanced UPS and DDLPS is slated for Q2 2026, with an IND submission for IOV-5001 in H1 2026. Selling, general, and administrative expenses are anticipated to increase with Amtagvi expansion and Proleukin marketing. The company believes it has sufficient capital to fund anticipated operating expenses and capital expenditures for at least the next twelve months.

Management Comments

• "Our mission is to be the global leader in innovating, developing, and delivering TIL cell therapies for patients with solid tumor cancers."
• "Our vision is to pioneer this transformational approach to cure solid tumor cancers."
• "We are committed to continuous innovation to develop TIL cell therapies and optimize TIL treatment regimens that may extend and improve life for patients with cancer."
• "Our top priority is to drive commercial success of Amtagvi for previously treated advanced melanoma."
• "We believe that we have sufficient capital to fund our anticipated operating expenses and capital expenditures as planned for at least the next twelve months following the issuance of our consolidated financial statements included in this Form 10-K."

Industry Context

StockSavvy.ai notes that Iovance Biotherapeutics operates in the highly competitive and rapidly evolving immuno-oncology space, particularly in cell therapies for solid tumors. The focus on Tumor Infiltrating Lymphocytes (TIL) represents a novel approach compared to single-antigen-targeted therapies, positioning Iovance as a pioneer. The challenges of complex manufacturing, stringent regulatory hurdles, and the need for significant capital are common across the biopharmaceutical industry, especially for companies developing advanced therapies. The withdrawal of the EU MAA and the past clinical hold on IOV-LUN-202 highlight the inherent risks and stringent regulatory environment for novel treatments. The company's strategy to expand its own manufacturing capacity (iCTC) aligns with a broader industry trend towards greater control over supply chains and cost efficiencies for complex biologics.

Comparison to Industry Standards

• Amtagvi's 31.4% Objective Response Rate (ORR) and 36.5 months median Duration of Response (mDOR) in previously treated advanced melanoma patients from the C-144-01 trial demonstrate unprecedented durability, potentially outperforming standard-of-care chemotherapy options like docetaxel monotherapy (which showed 12.8% ORR and 5.6 months mDOR in NSCLC, highlighting the potential for TIL therapy in solid tumors).
• The 65% ORR and 65% progression-free survival (PFS) at 6 and 12 months for lifileucel in combination with pembrolizumab in frontline advanced melanoma (IOV-COM-202 Cohort 1A) are highly competitive, especially when compared to existing immune checkpoint inhibitor (ICI) monotherapies or other ICI combinations in similar settings.
• The iCTC's potential capacity to supply TIL cell therapies for over 5,000 cancer patients annually is a significant scale for an autologous cell therapy, addressing a key challenge in the broader cell therapy industry which often struggles with manufacturing scalability and personalized production.
• The company's accumulated deficit of $2.8 billion and continued net losses are typical for a commercial-stage biopharmaceutical company heavily investing in R&D and commercialization of novel, high-cost therapies, similar to other early-to-mid stage gene or cell therapy developers.

Management Changes

Corporate Governance

Legal Proceedings

• Shumacher Derivative Lawsuit: Filed December 11, 2020, alleging breach of fiduciary duty and unjust enrichment regarding excessive non-executive director compensation. Proposed settlements in 2022 and 2024 were declined by the court. The case was consolidated in May 2025, and a motion to dismiss certain claims was filed on November 24, 2025. The company intends to vigorously defend against this matter.
• Ohio Laborers Derivative Lawsuit: Filed September 11, 2024, alleging breach of fiduciary duty in connection with the February 2024 public offering. An amended complaint was filed on December 5, 2024, and a second amended complaint on October 22, 2025. A motion to dismiss the second amended complaint was filed on December 12, 2025. The company intends to vigorously defend against this complaint.
• Solomon Capital, LLC Lawsuits (First and Second Solomon Suits): Complex litigation initiated in 2016 and 2019, involving alleged breach of contract, unjust enrichment, and fraud related to financing and intellectual property. In the First Solomon Suit, the company's motion for summary judgment was granted on December 3, 2025. In the Second Solomon Suit, the District Court entered judgment for the company on October 27, 2023, and the Solomon Plaintiffs' appeal was dismissed on November 8, 2024. A motion to vacate Rule 11 sanctions was denied on September 4, 2025. The company intends to vigorously defend these complaints and pursue its counterclaims.

Stakeholder Impact

• Shareholders: Face potential dilution from ongoing and future equity offerings, stock price volatility, and the financial and reputational risks associated with ongoing legal proceedings. The influence of principal stockholders remains significant.
• Employees: Affected by the August 2025 strategic restructuring plan, which included a 19% workforce reduction, leading to job losses and reallocation of responsibilities. The company continues to offer competitive compensation and benefits.
• Patients: Benefit from the commercial availability of Amtagvi for advanced melanoma and the potential for new TIL therapies in the pipeline for NSCLC, sarcomas, and other solid tumors. Risks include potential side effects from therapies and the importance of a robust Authorized Treatment Center (ATC) network for therapy delivery.
• Healthcare Professionals (HCPs) and Authorized Treatment Centers (ATCs): Require education, training, and collaboration for Amtagvi administration. Operational and patient support, along with favorable reimbursement, are crucial for adoption and patient access.
• Suppliers and Contract Manufacturing Organizations (CMOs): The company is transitioning Amtagvi/lifileucel manufacturing to its internal iCTC, reducing reliance on some CMOs, but continues to rely on others for next-generation therapies, posing risks related to performance and capacity.
• Creditors: The company's ongoing net losses and need for additional financing indicate a reliance on capital markets and potential future debt, impacting creditors' risk assessment.

Next Steps

• Launch Amtagvi into additional markets, with potential approvals pending in the UK and Australia in H1 2026, and Switzerland in 2027.
• Resubmit a centralized Marketing Authorization Application (MAA) for Amtagvi in the EU in 2026.
• Commence a registrational trial in previously treated advanced undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS) in Q2 2026, engaging with the FDA for expedited approval.
• Submit an Investigational New Drug (IND) application for IOV-5001 in H1 2026 to investigate it in a Phase 1/2 basket trial in solid tumors.
• Continue to drive commercial success of Amtagvi for previously treated advanced melanoma across four primary areas: educating healthcare professionals, providing operational and patient support, collaborating with payors for reimbursement, and driving operational excellence.
• Expand the Authorized Treatment Center (ATC) network for Amtagvi.
• Continue efforts to recruit a new Chief Executive Officer.
• Monitor and enhance cybersecurity protective measures.
• Evaluate the impact of adopting new accounting standards, including ASU 2024-03 and ASU 2025-05.

Key Dates

Recommendation

Iovance Biotherapeutics shows promising revenue growth for Amtagvi and a robust pipeline, indicating long-term potential in the solid tumor cancer market. However, the company continues to incur significant net losses and has an accumulated deficit of $2.8 billion, necessitating ongoing capital raises which dilute existing shareholders. Regulatory delays in key markets like the EU and past clinical holds introduce uncertainty. While the technology is innovative, the financial performance and operational challenges suggest a 'hold' recommendation, advising investors to monitor execution of commercialization, pipeline development, and progress towards profitability before making further investment decisions.

Keywords

TIL cell therapy, Amtagvi, lifileucel, melanoma, NSCLC, solid tumor cancer, biopharmaceutical, oncology, immunotherapy, Proleukin, aldesleukin, FDA approval, clinical trials, manufacturing, iCTC, gene editing, IOV-3001, IOV-4001, IOV-5001, corporate governance, financial results, SEC filing, 10-K, capital raise, restructuring